PMLiVE’s T40 – open for submissions!
Pharma Times
MARCH 28, 2024
Healthcare agencies can submit their entries free of charge with a deadline of 30 April
This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.
Pharma Times
MARCH 28, 2024
Healthcare agencies can submit their entries free of charge with a deadline of 30 April
Pharma Times
MARCH 28, 2024
Set to open in 2032, the RUEDI facility is funded by the UKRI’s recent infrastructure fund worth £388m
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
MARCH 28, 2024
The self-replicating mRNA molecule could be used in cancer and potentially a broad range of other diseases
Pharma Times
MARCH 27, 2024
The progressive and incurable brain disorder currently affects approximately 100 patients worldwide
Pharma Times
MARCH 26, 2024
According to the World Health Organization, TB is responsible for over one million annual deaths
Pharma Times
MARCH 22, 2024
Dementia is estimated to affect 850,000 people in the UK and costs the nation around £23bn a year
Pharma Times
MARCH 20, 2024
Rare kidney diseases are a group of conditions which account for over 5% of people living with chronic kidney disease
Pharma Times
MARCH 19, 2024
The SOL3D pipeline addresses research challenges in relation to equipment, expertise and cost
Pharma Times
MARCH 15, 2024
Every year, missed hospital appointments are estimated to cost the NHS £1.
Pharma Times
MARCH 14, 2024
Affecting 55 million people globally, dementia impairs the ability to remember, think or make decisions
Pharma Times
FEBRUARY 23, 2024
The immunosuppressant reduced inflammation in patients with the skin condition after three days
Pharma Times
FEBRUARY 22, 2024
The trial is recruiting patients in Leeds, Manchester, Oxford, London, Cambridge and Kent
Pharma Times
FEBRUARY 8, 2024
The committee has advised that the vaccine should be given to those at the highest risk
Pharma Times
FEBRUARY 7, 2024
The new products are in the areas of gastrointestinal and respiratory medicines
Pharma Times
FEBRUARY 6, 2024
Hypoxic-ischaemic encephalopathy affects around three million babies worldwide every year
Pharma Times
FEBRUARY 5, 2024
The aggressive brain cancer is responsible for over 3,000 cases in the UK every year
Pharma Times
FEBRUARY 5, 2024
The neurodegenerative condition currently affects over 944,000 people in the UK
Pharma Times
JANUARY 16, 2024
EUR 20m to identify new targets and develop first in class drugs
Pharma Times
JANUARY 15, 2024
CellVoyant’s platform combines AI with live cell imaging
Pharma Times
DECEMBER 15, 2023
The combined system works to detect and eliminate airborne pathogens A new air-filtering system developed by the University of Glasgow and Pinpoint Medical aims to detect and eliminate airborne pathogens to combat the spread of infections in hospitals. Funded by the UK Research and Innovations’ (UKRI) Engineering and Physical Sciences Research Council (EPSRC), the platform will decontaminate the air of pathogens and measure air quality to ensure a safer and healthier environment.
Pharma Times
DECEMBER 18, 2023
Earlier diagnosis could increase patient survival rates by five years or more The University of Glasgow has announced that an artificial intelligence (AI)-enhanced chest X-ray reporting solution has begun trials in NHS Greater Glasgow and Clyde (NHSGGC) for early detection of lung cancer. The Radiograph Accelerated Detection and Identification of Cancer of the Lung (RADICAL) trial is taking place at the Inverclyde Royal Hospital, the Vale of Leven Hospital and Paisley’s Royal Alexandria Hospital
Pharma Times
DECEMBER 20, 2023
Researchers from Johns Hopkins University School of Medicine have revealed new findings about a key pathological protein associated with Parkinson’s disease (PD), which could lead to new treatments. Published in Science Translational Medicine , the study found that the pathological form of alpha-synuclein triggers cells to increase protein synthesis in the neurodegenerative condition.
Pharma Times
DECEMBER 20, 2023
The Novo Nordisk Foundation has committed $260m to establish a new state-of-the-art research and vaccine development initiative to help combat deadly airborne infections. The initiative aims to create new or improved vaccines for deadly respiratory diseases, including tuberculosis (TB) and influenza. Developed in partnership with the University of Copenhagen and Denmark’s Statens Serum Institut, the vaccine initiative is the first-ever to focus on understanding how to generate immunity in the ai
Pharma Times
DECEMBER 12, 2023
Slow-growing cancer cells become more resistant to chemotherapy treatment - News - PharmaTimes
Pharma Times
DECEMBER 11, 2023
New data highlights the inequalities in emergency hospital rates and vaccinations - News - PharmaTimes
Pharma Times
NOVEMBER 24, 2023
Around 3,200 new cases of cervical cancer are diagnosed in the UK every year - News - PharmaTimes
Pharma Times
NOVEMBER 23, 2023
ADP101 is an oral immunotherapy to treat multi-food and single-food allergies - News - PharmaTimes
Pharma Times
NOVEMBER 22, 2023
The trial will use an AI screening platform to identify those most at risk of dementia - News - PharmaTimes
Pharma Times
OCTOBER 17, 2023
The two projects will investigate the potential causes of Parkinson’s disease - News - PharmaTimes
Pharma Times
OCTOBER 16, 2023
SOTIO will gain access to Synaffix’s three ADC technologies - News - PharmaTimes
Pharma Times
OCTOBER 13, 2023
The projects will support the development of new and longer-lasting vaccines - News - PharmaTimes
Pharma Times
OCTOBER 13, 2023
Automated analysis of language could help diagnose and assess psychiatric conditions - News - PharmaTimes
Pharma Times
OCTOBER 12, 2023
The service will benefit major research and industry projects across the UK - News - PharmaTimes
Pharma Times
AUGUST 30, 2023
The therapy involves treating individuals with atherosclerotic cardiovascular disease - News - PharmaTimes
Pharma Times
JULY 27, 2023
OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile - News - PharmaTimes
Pharma Times
JULY 25, 2023
The CB307 study expansion involves the addition of a new pembrolizumab combination cohort - News - PharmaTimes
Pharma Times
JULY 25, 2023
The company will utilise Qureight’s AI technology to undergo studies across a variety of complex lung diseases - News - PharmaTimes
Pharma Times
JULY 24, 2023
The treatment is a monotherapy for treating adult patients with refractory or relapsed multiple myeloma - News - PharmaTimes
Pharma Times
JULY 24, 2023
The drug is an injectable or tablet specifically developed for HIV prevention among certain individuals - News - PharmaTimes
Pharma Times
JULY 19, 2023
By combining both netarsudil and latanoprost treatment, Roclanda reduces intraocular pressure - News - PharmaTimes
Pharma Times
JUNE 27, 2023
The company is seeking to address the worldwide impact of group B streptococcus in older adults - News - PharmaTimes
Pharma Times
JUNE 27, 2023
Update on radiosensitising impact of SFX-01 when treating common soft tissue sarcoma condition - News - PharmaTimes
Pharma Times
JUNE 22, 2023
ATLX-1088 is regarded as a possible first-in-class human antibody targeting CD33 – a cell surface protein - News - PharmaTimes
Pharma Times
JUNE 16, 2023
DEVOTE grant will allow acute care patient access and a supporting infrastructure for the company - News - PharmaTimes
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content